Cocrystal Pharma (COCP) Asset Writedowns and Impairment (2010 - 2022)

Cocrystal Pharma (COCP) posted Asset Writedowns and Impairment of $19.1 million for Q2 2022, down 79.33% sequentially from $92.4 million in Q4 2016.

Cocrystal Pharma (COCP) Asset Writedowns and Impairment (2010 - 2022) Analysis & Trends

Cocrystal Pharma has reported Asset Writedowns and Impairment for 7 years, with the latest figure at $19.1 million in Q2 2022.

Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $19.1 million in Q2 2022, while the trailing twelve-month figure through Dec 2022 was $111.5 million (changed N/A YoY) and the FY2022 annual result came in at $19.1 million, changed N/A from the prior year.
Asset Writedowns and Impairment declined to $19.1 million in Q2 2022 per COCP's latest filing, from $92.4 million in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $19.1 million in Q2 2022 and troughed at $19.1 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Cocrystal Pharma	15.65 Mn	13.33 Mn	-

Download Data